Y, S., T, N., A, U., K, Y., M, M., K, Y., . . . Y, I. (2018). Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. Dove Medical Press.
Chicago Style (17th ed.) CitationY, Seko, et al. Efficacy and Safety of Canagliflozin in Type 2 Diabetes Mellitus Patients with Biopsy-proven Nonalcoholic Steatohepatitis Classified as Stage 1–3 Fibrosis. Dove Medical Press, 2018.
MLA (8th ed.) CitationY, Seko, et al. Efficacy and Safety of Canagliflozin in Type 2 Diabetes Mellitus Patients with Biopsy-proven Nonalcoholic Steatohepatitis Classified as Stage 1–3 Fibrosis. Dove Medical Press, 2018.
Warning: These citations may not always be 100% accurate.